----
Current ValuationThe current P/E ratio is -12.05, below the reasonable range, cheaper than 95.86% of the time in the past 5 years, and the industry ranks 475/606, the industry Median -1.90.
-12.05xP/E
$3.35Stock price
$-0.28Earnings per share
-12.05xP/E
Stock price$3.35Earnings per share$-0.28
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -3.15x
- Typical range
- -5.37x–-2.27x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -53.77x | 161.61% | $207.66B |
MRNAUSModerna | -28.94x | 16.99% | $91.20B |
CSLLYUSCSL Limited | -25.73x | -- | $66.36B |
NTRAUSNatera | -291.24x | 5.57% | $56.02B |
RVMDUSRevolution Medicines | -23.54x | 61.94% | $41.63B |
ROIVUSRoivant Sciences | -97.77x | 146.69% | $26.03B |
INSMUSInsmed | -37.66x | 75.15% | $22.81B |
BNTXUSBioNTech SE | -11.17x | 22.98% | $21.83B |
BBIOUSBridgebio Pharma | -24.44x | 31.08% | $14.47B |
SMMTUSSummit Therapeutics | -14.72x | 20.06% | $12.60B |
KYMRUSKymera Therapeutics | -30.24x | 8.45% | $10.57B |
PCVXUSVaxcyte | -8.99x | 47.91% | $9.57B |
TWSTUSTwist Bioscience | -67.56x | 28.63% | $9.24B |
MDGLUSMadrigal Pharma | -28.17x | 50.98% | $9.16B |
IBRXUSImmunityBio | -8.85x | 151.32% | $8.79B |
SYREUSSpyre Therapeutics | -58.27x | 45.60% | $8.75B |
CYTKUSCytokinetics | -9.69x | 7.04% | $8.66B |
ARWRUSArrowHead Pharma | -26.28x | 35,923.70% | $8.41B |
PRAXUSPraxis Precision Medicines | -23.09x | 3.71% | $7.83B |
IONSUSIonis Pharma | -11.89x | 49.51% | $6.72B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
